Advertisement

Does aggressive local therapy improve survival in metastatic breast cancer?

      Abstract

      Background. Women with metastatic breast cancer and an intact primary tumor are currently treated with systemic therapy. Local therapy of the primary tumor is considered irrelevant to the outcome, and is recommended only for palliation of symptoms. Methods. We have examined the use of local therapy, and its impact on survival in patients presenting with stage IV breast cancer at initial diagnosis, who were reported to the National Cancer Data Base (NCDB) between 1990 and 1993. Results. A total of 16,023 patients with stage IV disease were identified in the NCDB during this period, of whom 6861 (42.8%) received either no operation or a variety of diagnostic or palliative procedures, and 9162 (57.2%) underwent partial (3513) or total (5649) mastectomy. The presence of free surgical margins was associated with an improvement in 3-year survival in partial or total mastectomy groups (26% vs 35%, respectively). A multivariate proportional hazards model identified the number of metastatic sites, the type of metastatic burden, and the extent of resection of the primary tumor as significant independent prognostic covariates. Women treated with surgical resection with free margins, when compared with those not surgically treated, had superior prognosis, with a hazard ratio of 0.61 (95% confidence interval 0.58,0.65). Conclusions. These data suggest that the role of local therapy in women with stage IV breast cancer needs to be re-evaluated, and local therapy plus systemic therapy should be compared with systemic therapy alone in a randomized trial. Surgery 2002;132:620-7.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Flanigan RC
        • Salmon SE
        • Blumenstein BA
        • Bearman SI
        • Roy V
        • McGrath PC
        • Caton Jr, JR
        • Munshi N
        • Crawford ED
        Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
        N Engl J Med. 2001; 345: 1655-1659
        • Menck HR
        • Bland KI
        • Scott-Conner CE
        • Eyre HJ
        • Murphy GP
        • Winchester DP
        Regional diversity and breadth of the National Cancer Data Base.
        Cancer. 1998; 83: 2649-2658
        • Stewart AK
        • Bland KI
        • McGinnis Jr, LS
        • Morrow M
        • Eyre HJ
        Clinical highlights from the National Cancer Data Base, 2000.
        CA Cancer J Clin. 2000; 50: 171-183
      1. International classification of diseases for oncology. World Health Organization;, Switzerland, Geneva1992
        • Beahrs O
        Manual for staging of cancer.
        Lippincott, Philadelphia1992
        • Marubini E
        Analyzing survival data from clinical trials and observational studies.
        John Wiley and Sons, New York1995
        • Cox DR
        Regression models and life tables.
        Journal of the Royal Statistical Society: Series B. 1972; 34: 187-220
        • Arriagada R
        • Rutqvist LE
        • Mattsson A
        • Kramar A
        • Rotstein S
        Adequate locoregional treatment for early breast cancer may prevent secondary dissemination.
        Journal of Clinical Oncology. 1995; 13: 2869-2878
        • Fisher B
        • Montague E
        • Redmond C
        • Deutsch M
        • Brown GR
        • Zauber A
        • et al.
        Findings from NSABP protocol No. B-04-comparison of radical mastectomy with alternative treatments for primary breast cancer, I: radiation compliance and its relation to treatment outcome.
        Cancer. 1980; 46: 1-13
        • Ragaz J
        • Jackson SM
        • Le N
        • Plenderleith IH
        • Spinelli JJ
        • Basco VE
        • et al.
        Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
        N Engl J Med. 1997; 337: 956-962
        • Overgaard M
        • Hansen PS
        • Overgaard J
        • Rose C
        • Andersson M
        • Bach F
        • et al.
        Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy.
        N Engl J Med. 1997; 337: 949-955
        • Overgaard M
        • Jensen MB
        • Overgaard J
        • Hansen PS
        • Rose C
        • Andersson M
        • et al.
        Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial.
        Lancet. 1999; 353: 1641-1648
        • Holmes FA
        • Buzdar AU
        • Kau S-W
        • Fraschini G
        • Ames FC
        • McNeese MD
        • Hortobagyi GN
        Combined modality approach for patients with isolated recurrences of breast cancer (IV-NED): the MD Anderson experience.
        Breast Disease. 1994; 7: 7-20
        • Nieto Y
        • Nawaz S
        • Jones RB
        • Shpall EJ
        • Cagnoni PJ
        • McSweeney PA
        • et al.
        Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.
        J Clin Oncol. 2002; 20: 707-718
        • Rahman ZU
        • Frye DK
        • Smith TL
        • Asmar L
        • Theriault RL
        • Buzdar AU
        • et al.
        Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
        Cancer. 1999; 85: 104-111
        • Hallissey MT
        • Allum WH
        • Roginski C
        • Fielding JW
        Palliative surgery for gastric cancer.
        Cancer. 1988; 62: 440-444
        • Rosen SA
        • Buell JF
        • Yoshida A
        • Kazsuba S
        • Hurst R
        • Michelassi F
        • et al.
        Initial presentation with stage IV colorectal cancer: how aggressive should we be?.
        Arch Surg. 2000; 135: 530-534